BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 20300841)

  • 1. Esophageal adenocarcinoma: treatment modalities in the era of targeted therapy.
    Mukherjee K; Chakravarthy AB; Goff LW; El-Rifai W
    Dig Dis Sci; 2010 Dec; 55(12):3304-14. PubMed ID: 20300841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Target Therapy for Esophageal Adenocarcinoma.
    Lam KO; Kwong DLW
    Methods Mol Biol; 2018; 1756():51-65. PubMed ID: 29600359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of Patients With Adenocarcinoma or Squamous Cancer of the Esophagus.
    Ilson DH; van Hillegersberg R
    Gastroenterology; 2018 Jan; 154(2):437-451. PubMed ID: 29037469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy for esophageal cancer.
    Heath EI; Forastiere AA
    Cancer Treat Res; 2001; 105():387-98. PubMed ID: 11224996
    [No Abstract]   [Full Text] [Related]  

  • 5. New developments in the treatment of esophageal cancer.
    Ilson DH
    Clin Adv Hematol Oncol; 2004 Feb; 2(2):97-104. PubMed ID: 16163169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Multimodality therapy concepts in esophageal carcinoma].
    Siewert JR; Ott K
    Kongressbd Dtsch Ges Chir Kongr; 2001; 118():39-43. PubMed ID: 11824282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor-directed therapy in esophageal cancer.
    Pande AU; Iyer RV; Rani A; Maddipatla S; Yang GY; Nwogu CE; Black JD; Levea CM; Javle MM
    Oncology; 2007; 73(5-6):281-9. PubMed ID: 18477853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent developments in esophageal adenocarcinoma.
    Lagergren J; Lagergren P
    CA Cancer J Clin; 2013; 63(4):232-48. PubMed ID: 23818335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer of the esophagus and stomach.
    Khushalani N
    Mayo Clin Proc; 2008 Jun; 83(6):712-22. PubMed ID: 18533089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does Barrett's esophagus respond to chemoradiation therapy for adenocarcinoma of the esophagus?
    Barthel JS; Kucera ST; Lin JL; Hoffe SE; Strosberg JR; Ahmed I; Dilling TJ; Stevens CW
    Gastrointest Endosc; 2010 Feb; 71(2):235-40. PubMed ID: 20003971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Introduction: Esophageal Adenocarcinoma: Updates of Current Status.
    Lam AK
    Methods Mol Biol; 2018; 1756():1-6. PubMed ID: 29600355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant chemoradiation therapy in patients with surgically treated esophageal cancer.
    Vermund H; Pories WJ; Hillard J; Wiley AL; Youngblood R
    Acta Oncol; 2001; 40(5):558-65. PubMed ID: 11669326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiogenic switch in Barrett's adenocarcinoma: the role of vascular endothelial growth factor.
    Islam A; Banerjee S; Kambhampati S; Baranda J; Banerjee S; Weston AP; Saxena NK; Banerjee SK
    Front Biosci; 2006 Sep; 11():2336-48. PubMed ID: 16720317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting key signalling pathways in oesophageal adenocarcinoma: a reality for personalised medicine?
    Keld RR; Ang YS
    World J Gastroenterol; 2011 Jun; 17(23):2781-90. PubMed ID: 21734785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of Bcl-2 expression in Barrett's dysplasia and adenocarcinoma is associated with tumor progression and worse survival but not with response to neoadjuvant chemoradiation.
    Raouf AA; Evoy DA; Carton E; Mulligan E; Griffin MM; Reynolds JV
    Dis Esophagus; 2003; 16(1):17-23. PubMed ID: 12581249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of pretherapeutic expression of chemotherapy-related genes with response to neoadjuvant chemotherapy in Barrett carcinoma.
    Langer R; Specht K; Becker K; Ewald P; Bekesch M; Sarbia M; Busch R; Feith M; Stein HJ; Siewert JR; Höfler H
    Clin Cancer Res; 2005 Oct; 11(20):7462-9. PubMed ID: 16243820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical analysis of 108 cases with adenocarcinoma Barretts's esophagus].
    Han JQ; Liu Q; Liang RX; Qu FS; Yan TX; Sun YH; Li XQ
    Zhonghua Zhong Liu Za Zhi; 2007 Jun; 29(6):470-3. PubMed ID: 17974287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
    Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
    Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Barrett's esophagus with high-grade dysplasia.
    McAllaster JD; Buckles D; Al-Kasspooles M
    Expert Rev Anticancer Ther; 2009 Mar; 9(3):303-16. PubMed ID: 19275509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer of the gastroesophageal junction: combined modality therapy.
    Ilson DH
    Surg Oncol Clin N Am; 2006 Oct; 15(4):803-24. PubMed ID: 17030275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.